MDS Inc. Announces Normal Course Issuer Bid
30 Giugno 2008 - 2:00PM
PR Newswire (US)
TORONTO, June 30 /PRNewswire-FirstCall/ -- MDS Inc. (TSX: MDS,
NYSE: MDZ), a leading provider of enabling products and services to
the global life sciences markets, announced today that the Toronto
Stock Exchange (TSX) accepted the Company's Notice of Intention to
make a normal course issuer bid for a one-year period. The Notice
provides that during the twelve months commencing July 3, 2008 and
ending July 2, 2009, if deemed appropriate by the Chief Executive
Officer and Chief Financial Officer of the Company, MDS may
purchase up to 4,136,766 MDS Common shares on the Toronto Stock
Exchange and the New York Stock Exchange. This represents
approximately 5% of the public float. At June 20, 2008, there were
122,028,330 Common shares issued and outstanding and 82,735,313
Common shares in the public float. All shares purchased by MDS
under this normal course issuer bid will be promptly cancelled.
Daily purchases will be limited to 130,250 Common shares, other
than block purchase exceptions. Under the Company's previous normal
course issuer bid, which began on July 3, 2007 and ends on July 2,
2008, MDS has purchased and cancelled 1,235,300 Common shares to
date. Since all purchases of MDS Common shares under the normal
course issuer bid would be made on the open market, the Company is
not in a position to know the identity of the parties from whom it
may purchase Common shares. The Company believes that the purchase
of outstanding Common shares at certain times during the normal
course issuer bid period may enhance value for shareholders and is
an appropriate use of funds. This document contains forward-looking
statements. Some forward-looking statements may be identified by
words like "expects", "anticipates", "plans", "intends",
"indicates" or similar expressions. The statements are not a
guarantee of future performance and are inherently subject to risks
and uncertainties. The Company's actual results could differ
materially from those currently anticipated due to a number of
factors, including, but not limited to, successful integration of
structural changes, including restructuring plans, acquisitions,
technical or manufacturing or distribution issues, the competitive
environment for the Company's products, the degree of market
penetration of the Company's products, and other factors set forth
in reports and other documents filed by the Company with Canadian
and US securities regulatory authorities from time to time. About
MDS MDS Inc. (TSX: MDS; NYSE: MDZ) is a global life sciences
company that provides market-leading products and services for the
development of drugs and diagnosis and treatment of disease. We are
a leading global provider of pharmaceutical contract research,
medical isotopes for molecular imaging, radiotherapeutics, and
analytical instruments. MDS Inc. has more than 5,500 highly skilled
people in 29 countries. Find out more at http://www.mdsinc.com/ or
by calling 1-888-MDS-7222, 24 hours a day. DATASOURCE: MDS Inc.
CONTACT: Investors: Kim Lee, MDS Inc., (416) 675-6777 x 34721, ;
Media: Janet Ko, MDS Inc., (416) 675-6777 x 34167,
Copyright